❗Help close the gap: We still need to raise $40,000 by the end of March. Donate now

Christopher Werth

Latest Stories (242)

Volkswagen beats the odds in Europe

Nov 30, 2012
As other carmakers in Europe struggle for their very survival, VW is flourishing thanks in part to its worldwide appeal.

GM looks to close German autoplant

Nov 29, 2012
Strong unions and labor laws have kept struggling carmakers from cutting plants in Germany, but that may be about to change.

Peugeot: Rescued, but constrained by bailout

Nov 28, 2012
Last month, Peugeot secured a $9 billion lifeline from the French government to stay out of bankruptcy. In return, French politicians want the struggling company keep jobs, not cut them.

European automakers face dark present, uncertain future

Nov 27, 2012
Carmakers in Europe are seeing plunging sales and rising costs -- sound familiar? Will European automakers rebound like their U.S. competitors?

Despite Spanish downturn, many immigrants stay

Nov 5, 2012
A lack of jobs has not convinced many immigrants who came to Spain during better times to leave.

Spain continues bailout waiting game

Oct 18, 2012
For months now, Spain has been bracing itself for a bailout. While the country waits, the government has already made many of the deep budget cuts that typically come with bailouts.

In Northern Spain, hard times stir separatist feelings

Oct 16, 2012
In the Northern Spanish region of Catalonia, many say they would be better to go it alone. This rich region puts more into the central government than it gets out and Catalans are starting to resent this.

Spain's government announces tough new budget

Sep 27, 2012
In further austerity measures, the government imposes some $50 billion of tax hikes and spending cuts

Budget cuts causing more strain in Spain

Sep 27, 2012
Today the government of Spain is expected to lay out yet another new budget with even more cuts in it.

Indian court case crucial for cancer sufferers

Sep 12, 2012
This week, India's Supreme Court hears arguments in a case that will affect how many poor people can afford cancer drugs. Novartis is defending a patent on its cancer medication, Gleevec.